BARDA and Partner Therapeutics foster a new partnership around their FDA-approved drug, Leukine® to improve patient care for sepsis patients

 

Lexington, MA – September 20, 2021 /PRNewswire/ — Partner Therapeutics, Inc. (PTx) announced a collaboration with the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, and Labcorp Drug Development to advance a new diagnostic approach to select immunoparalyzed sepsis patients that could benefit most from Leukine (sargramostim).  Through advancement of a Laboratory Developed Test (LDT) for monocyte ...

Continue Reading →
0

“A Drug Before Its Time?” LEUKINE® systematic review highlights innate and adaptive immune activity that may improve cancer outcomes and reduce toxicity

Authors also highlight promising data in neurodegenerative diseases, fungal infection, and respiratory diseases including aPAP and COVID-19

Lexington, MA – August 17, 2021 /PRNewswire/ — Partner Therapeutics, Inc. (PTx) announced today that Frontiers in Immunology published a systematic review of LEUKINE® titled, “Sargramostim (rhu GM-CSF) as Cancer Therapy (Systematic Review) and An Immunomodulator.  A Drug Before Its Time?” This manuscript chronicles Leukine’s 30-year history in oncology research, including 27 studies that each enrolled 50 or more patients.  Importantly, this ...

Continue Reading →
0

Second Randomized Trial of Leukine® (sargramostim) in COVID-19 Demonstrates Improvement in Lung Function

Department of Defense (DOD) Sponsored U.S. Study Met Primary Endpoint for Improvement in Oxygenation and Demonstrated Treatment with Inhaled Leukine Was Safe and Well Tolerated

Lexington, MA – June 28, 2021 /PRNewswire/ — Partner Therapeutics, Inc. (PTx) announced top-line results of the U.S.-based iLeukPulm clinical trial of inhaled Leukine (sargramostim, yeast-derived recombinant human granulocyte macrophage colony stimulating factor (GM-CSF)) in hospitalized COVID-19 patients (NCT04411680).1  This prospective, randomized, controlled, open-label study was conducted at 11 U.S. hospitals.  The ...

Continue Reading →
0

Partner Therapeutics Announces Publication of Clinical Trial Results of Leukine® (sargramostim) in Patients with Parkinson’s Disease

Immune transformation after intermittent dosing with Leukine shows promise for Parkinson’s disease

LEXINGTON, MA – May 19, 2021 — Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces the publication of results from an investigator-initiated clinical trial (NCT03790670) evaluating the use of Leukine® (sargramostim, yeast-derived rhuGM-CSF) in patients with Parkinson’s Disease. Participants were evaluated for safety and tolerability as well as disease signs and symptoms including a standard Parkinson’s mobility test (Movement Disorder Society (MDS) – Unified ...

Continue Reading →
0

Partner Therapeutics Initiates Patient Enrollment in Clinical Trial Evaluating Leukine® (rhuGM-CSF, sargramostim) in High-risk Non-hospitalized COVID-19 Patients (SCOPE)

Focus on non-hospitalized patients based on prior data supporting Leukine’s role in improving lung function and enhanced COVID-19 specific immune response

LEXINGTON, MA – April 29, 2021 — Partner Therapeutics, Inc. (PTx), a commercial biotechnology company, announced today that the first patient has been enrolled in the SCOPE clinical trial, a randomized, placebo-controlled, double-blind phase 2 study of inhaled Leukine (sargramostim, rhu-GM-CSF) in 400 non-hospitalized COVID-19 patients (NCT04707664) at higher risk for progression to more severe COVID-19.  ...

Continue Reading →
0

Partner Therapeutics Announces Publication of Clinical Trial Results Showing Significant Benefit with Use of Leukine® (sargramostim) in Patients with Alzheimer’s Disease

Patients with mild-to-moderate Alzheimer’s disease (AD) receiving Leukine experienced significant reversal of cognitive loss and biomarkers of disease progression while taking Leukine

Study shows Leukine safe and tolerable and concludes that the innate immune system is a viable target for therapeutic intervention in AD

Lexington, MA – March 24, 2021 — Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces the publication of results from an investigator-initiated clinical trial (NCT01409915) evaluating the use of Leukine® (sargramostim, yeast-derived rhuGM-CSF) in patients ...

Continue Reading →
0

Partner Therapeutics Announces Partnership with SIRS Therapeutics and F4 Pharma to Explore Potential Uses for FX06 in Biodefense Applications

FX-06 is a synthetic peptide with a broad spectrum of potential applications associated with endothelial barrier integrity, blood vessel permeability and inflammation

Potential applications include COVID-19, pandemic, chemical, biological, radiological and nuclear threats

Lexington, MA – March 3, 2021 — Partner Therapeutics, Inc. (PTx), a commercial biotech company, announces a licensing and collaboration agreement with Munich-based SIRS Therapeutics and Vienna-based F4 Pharma to support the development of FX-06, a synthetic peptide that has a broad spectrum of potential indications. The partnership will ...

Continue Reading →
0

SARPAC Clinical Trial of Leukine® (sargramostim, rhu GM-CSF) in Hospitalized COVID-19 Patients Meets Primary Endpoint of Significant Improvement in Lung Function

Improvement in lung function measured by oxygenation levels and markers for disease severity and lung fibrosis

Treatment with sargramostim was safe, well tolerated and generated T-cells targeted at the SARS-CoV-2 virus, indicating a COVID-19 specific immune response

Lexington, MA – February 26, 2021 /PRNewswire/ — Partner Therapeutics, Inc. (PTx) announced top-line results today of the investigator-led SARPAC (Sargramostim in Patients with Acute Hypoxic Respiratory Failure and Acute COVID-19) study of inhaled Leukine® (sargramostim, yeast-derived recombinant human GM-CSF) in hospitalized COVID-19 patients ...

Continue Reading →
0

Partner Therapeutics Announces Publication of Two Studies Demonstrating Leukine® Improves Survival in Acute Radiation Syndrome (ARS)

Studies Showed Statistically Significant Improvements in Survival in Subjects Treated with Leukine Starting 48 Hours After Acute, High Dose Radiation Exposure without Need for Blood Transfusions or Other Forms of Intensive Supportive Care 

Leukine Administration Starting 48, 72, 96 and 120 Hours after Lethal Radiation Exposure:

    • Enhanced Recovery of Platelets, Lymphocytes, Neutrophils and Reticulocytes
    • Reduced Frequency, Severity and Duration of Infection, Septicemia and Hemorrhage1

 Studies Provided the Basis for FDA Approval of Leukine for Treatment of Myelosuppression and Hematopoietic Damage and Dysfunction ...

Continue Reading →
0

Partner Therapeutics (PTx) Announces the Appointment of Ed Rock as Chief Medical Officer

Experienced industry physician scientist to lead clinical development; Co-founder, Dr. Debasish Roychowdhury, to serve as Chief Technology Officer

Lexington, MA – September 15, 2020/ PR Newswire/ – Partner Therapeutics, Inc. (PTx), a commercial biotechnology company, announced today its appointment of Edwin Rock, MD, PhD to serve as the company’s Chief Medical Officer. In his role as CMO, Dr. Rock will oversee clinical development activities for PTx, as well as serve on the Company’s executive leadership team.

Dr. Rock has ...

Continue Reading →
0
Page 1 of 2 12